Addressing the rise of multiple myeloma in Rwanda

Intervention of osteoclastogenesis that occurs in breast cancer and multiple myeloma

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia

Isa-VCd induction in NDMM patients with severe renal impairment show no new safety concerns

A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM

Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms

EHA 2024: Multiple myeloma roundup

ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line

Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia

More effective treatment options required for patients with MM post lenalidomide exposure